Favipiravir is a pyrazine-based antiviral agent primarily indicated for the treatment of resistant influenza, including influenza A and B, as well as avian influenza. Functioning as a broad-spectrum antiviral,… Read more

















































Favipiravir is a pyrazine-based antiviral agent primarily indicated for the treatment of resistant influenza, including influenza A and B, as well as avian influenza. Functioning as a broad-spectrum antiviral, it works by inhibiting the viral RNA-dependent RNA polymerase (RdRp) enzyme, effectively blocking the transcription and replication of viral genomes. To ensure the safety and efficacy of this therapeutic agent, pharmaceutical laboratories rely on a comprehensive range of related compounds, including pharmaceutical reference standards, impurity profiling markers, and metabolites like favipiravir-5-hydroxy. Additionally, stable isotope labelled compounds are essential tools for conducting accurate analytical testing, method validation, and quality control. This collection provides the necessary materials to support the rigorous analysis of favipiravir, its reaction impurities, and structural analogues throughout the drug development and manufacturing lifecycle.